All Stories

  1. Education shares distinct genetic influences with substance use and disorder
  2. Phenome-wide analysis of genetically imputed neuroimaging phenotypes reveals associations with psychiatric traits in a multi-ancestry cohort
  3. Racial and ethnic disparities in buprenorphine retention and treatment outcome in a longitudinal cohort of U.S. veterans with opioid use disorder
  4. Whole-exome sequencing study of opioid dependence offers novel insights into the contributions of exome variants
  5. The genetics of cannabis lifetime use
  6. Multi-ancestry Genome-wide Association Study of Inpatient Opioid Dosing Following Knee or Hip Arthroplasty
  7. Polygenic risk and childhood adversity as moderators of drug and alcohol withdrawal symptoms
  8. Multi-ancestry Genome-wide Association Study of Inpatient Opioid Dosing Following Knee or Hip Arthroplasty
  9. Disaggregating the Genetic Overlap Between Educational Attainment and Substance Use Phenotypes
  10. Moderation of treatment outcomes by polygenic risk for alcohol‐related traits in placebo‐controlled trials of topiramate
  11. Multi‐ancestry genome‐wide association study of topiramate's effects on heavy alcohol use
  12. A single-cell genomic atlas for the effects of chronic ethanol exposure in the mouse dorsal striatum
  13. Gene discovery and pleiotropic architecture of chronic pain in a genome-wide association study of >1.2 million individuals
  14. Social network alcohol use is associated with individual‐level alcohol use among Black sexually minoritized men and gender‐expansive people: Findings from the Neighborhoods and Networks (N2) cohort study
  15. Communication-efficient federated learning of temporal effects on opioid use disorder with data from distributed research networks
  16. Associations of Childhood Adversity and Polygenic Scores with Substance Use Initiation and Disorder Severity
  17. Associations of Childhood Adversity and Polygenic Scores with Substance Use Initiation and Disorder Severity – ERRATUM
  18. Integrating HiTOP and RDoC frameworks Part I: Genetic architecture of externalizing and internalizing psychopathology
  19. Integrating HiTOP and RDoC frameworks part II: shared and distinct biological mechanisms of externalizing and internalizing psychopathology
  20. A Mendelian randomization study of alcohol use and cardiometabolic disease risk in a multi‐ancestry population from the Million Veteran Program
  21. Addressing Disparities in Alcohol Use Disorder Treatment: A Call to Action
  22. Considerations for the application of polygenic scores to clinical care of individuals with substance use disorders
  23. Association patterns of antisocial personality disorder across substance use disorders
  24. A genome-wide investigation into the underlying genetic architecture of personality traits and overlap with psychopathology
  25. Application of polygenic scores to a deeply phenotyped sample enriched for substance use disorders reveals extensive pleiotropy with psychiatric and somatic traits
  26. Identifying neurofunctional domains across substance use disorders
  27. Gene × environment effects and mediation involving adverse childhood events, mood and anxiety disorders, and substance dependence
  28. Combining Transdiagnostic and Disorder-Level GWAS Enhances Precision of Psychiatric Genetic Risk Profiles in a Multi-Ancestry Sample
  29. Welcoming ACER's new Editor
  30. Integrating HiTOP and RDoC Frameworks Part I: Genetic Architecture of Externalizing and Internalizing Psychopathology
  31. A Multivariate Genome-Wide Association Study Reveals Neural Correlates and Common Biological Mechanisms of Psychopathology Spectra
  32. Genetic and non-genetic predictors of risk for opioid dependence
  33. Reductions in WHO risk drinking levels correlate with alcohol craving among individuals with alcohol use disorder
  34. Prevalence and correlates of DSM-5 opioid withdrawal syndrome in U.S. adults with non-medical use of prescription opioids: results from a national sample
  35. Comparing the Psychometric Properties of Reward and Relief Drinking Measures
  36. Adverse Childhood Events, Mood and Anxiety Disorders, and Substance Dependence: Gene x Environment Effects and Moderated Mediation
  37. Adverse Childhood Events, Mood and Anxiety Disorders, and Substance Dependence: Gene X Environment Effects and Moderated Mediation
  38. Demographic differences in the cascade of care for unhealthy alcohol use: A cross‐sectional analysis of data from the 2015–2019 National Survey on Drug Use and Health
  39. Medications for treating alcohol use disorder: A narrative review
  40. Genetic Underpinnings of the Transition From Alcohol Consumption to Alcohol Use Disorder: Shared and Unique Genetic Architectures in a Cross-Ancestry Sample
  41. Identifying genetic loci and phenomic associations of substance use traits: A multi‐trait analysis of GWAS (MTAG) study
  42. Metabolic Profiles Associated with Opioid Use and Opioid Use Disorder: a Narrative Review of the Literature
  43. Does polygenic risk for substance‐related traits predict ages of onset and progression of symptoms?
  44. Multi-trait genome-wide association analyses leveraging alcohol use disorder findings identify novel loci for smoking behaviors in the Million Veteran Program
  45. Racial and Ethnic Bias in the Diagnosis of Alcohol Use Disorder in Veterans
  46. The genetic architecture of pain intensity in a sample of 598,339 U.S. veterans
  47. Effects of topiramate therapy on serum bicarbonate concentration in a sample of 10,279 veterans
  48. An intensive longitudinal examination of topiramate treatment for alcohol use disorder: a secondary analysis of data from a randomized controlled trial
  49. Announcing a name change for ACER
  50. Polygenic Risk for Substance-Related Traits Predicts Substance Use Onset and Progression: Sex and Population Group Differences
  51. A randomized, double‐blind, placebo‐controlled, pharmacogenetic study of ondansetron for treating alcohol use disorder
  52. Integrating human brain proteomic data with genome-wide association study findings identifies novel brain proteins in substance use traits
  53. Association of topiramate prescribed for any indication with reduced alcohol consumption in electronic health record data
  54. Using 18F-NOS PET Imaging to Measure Pulmonary Inflammation in Electronic and Combustible Cigarette Users: A Pilot Study
  55. Association of Topiramate Prescribed for any Indication with Reduced Alcohol Consumption in Electronic Health Record Data
  56. Is it time to rethink low‐risk drinking guidelines?
  57. Associations between alcohol consumption and gray and white matter volumes in the UK Biobank
  58. Alcohol withdrawal in past‐year drinkers with unhealthy alcohol use: Prevalence, characteristics, and correlates in a national epidemiologic survey
  59. Using phenotype risk scores to enhance gene discovery for generalized anxiety disorder and posttraumatic stress disorder
  60. Within‐ and between‐person effects of naltrexone on the subjective response to alcohol and craving: A daily diary investigation
  61. Genome-wide meta-analysis of alcohol use disorder in East Asians
  62. Post‐treatment effects of topiramate on alcohol‐related outcomes: A combined analysis of two placebo‐controlled trials
  63. Identifying and Reducing Bias in Genome-Wide Association Studies of Alcohol-Related Traits
  64. Placebo-controlled trial of bupropion for smoking cessation in pregnant women
  65. Genetic liability for substance use associated with medical comorbidities in electronic health records of African‐ and European‐ancestry individuals
  66. Analysis of genetic and clinical factors associated with buprenorphine response
  67. Combined analysis of the moderating effect of a GRIK1 polymorphism on the effects of topiramate for treating alcohol use disorder
  68. Comorbid-phenome prediction and phenotype risk scores enhance gene discovery for generalized anxiety disorder and posttraumatic stress disorder
  69. World Health Organization risk drinking levels as a treatment outcome measure in topiramate trials
  70. Genome-wide association study of stimulant dependence
  71. The impact of removing former drinkers from genome‐wide association studies of AUDIT‐C
  72. Accuracy of Consumer‐marketed smartphone‐paired alcohol breath testing devices: A laboratory validation study
  73. Correction to: Prospective randomized pharmacogenetic study of topiramate for treating alcohol use disorder
  74. The phenomics and genetics of addictive and affective comorbidity in opioid use disorder
  75. Reward drinking and naltrexone treatment response among young adult heavy drinkers
  76. Prospective randomized pharmacogenetic study of topiramate for treating alcohol use disorder
  77. Effects of topiramate on neural responses to alcohol cues in treatment-seeking individuals with alcohol use disorder: preliminary findings from a randomized, placebo-controlled trial
  78. Epigenomic Profiles of African-American Transthyretin Val122Ile Carriers Reveals Putatively Dysregulated Amyloid Mechanisms
  79. Genetic underpinnings of risky behaviour relate to altered neuroanatomy
  80. Multi-environment gene interactions linked to the interplay between polysubstance dependence and suicidality
  81. A Delta-Opioid Receptor Gene Polymorphism Moderates the Therapeutic Response to Extended-Release Buprenorphine in Opioid Use Disorder
  82. Pregnant Smokers Receiving Opioid Agonist Therapy Have an Elevated Nicotine Metabolite Ratio: A Replication Study
  83. World Health Organization Risk Drinking Level Reductions Are Associated with Improved Functioning and Are Sustained Among Patients with Mild, Moderate, and Severe Alcohol Dependence in Clinical Trials in the United States and United Kingdom
  84. An analysis of the effect of mu-opioid receptor gene (OPRM1) promoter region DNA methylation on the response of naltrexone treatment of alcohol dependence
  85. Genome-Wide Association Study of Opioid Cessation
  86. Author Correction: Genomewide Study of Epigenetic Biomarkers of Opioid Dependence in European- American Women
  87. Genomewide Gene-by-Sex Interaction Scans Identify ADGRV1 for Sex Differences in Opioid Dependent African Americans
  88. A regulatory variant of CHRM3 is associated with cannabis-induced hallucinations in European Americans
  89. Author Correction: Genome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations
  90. A meta‐analysis of the efficacy of gabapentin for treating alcohol use disorder
  91. Author Correction: Genome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations
  92. Genome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations
  93. Reduction in non-abstinent WHO drinking risk levels and depression/anxiety disorders: 3-year follow-up results in the US general population
  94. Genomewide Study of Epigenetic Biomarkers of Opioid Dependence in European- American Women
  95. Alcohol-responsive genes identified in human iPSC-derived neural cultures
  96. GWAS and network analysis of co-occurring nicotine and alcohol dependence identifies significantly associated alleles and network
  97. Genome-wide association study identifies glutamate ionotropic receptor GRIA4 as a risk gene for comorbid nicotine dependence and major depression